Residency · Residency · Chronic Pain Management
Opioid Prescribing for Chronic Non-Cancer Pain
Introduction
Opioid prescribing for chronic non-cancer pain (CNCP) remains one of the most debated topics in pain medicine. The opioid crisis has prompted a critical reexamination of practices that were commonplace during the "pain as the fifth vital sign" era. Current evidence-based practice demands careful patient selection, informed consent, structured monitoring, and realistic expectations regarding long-term outcomes. This lecture reviews the CDC guidelines, patient selection frameworks, treatment agreements, dose limitations, and the surprisingly thin evidence base for long-term opioid therapy.
CDC Clinical Practice Guideline (2022 Revision)
The 2022 CDC Clinical Practice Guideline for Prescribing Opioids replaced the 2016 guideline with 12 recommendations organized into four areas.
Determining Whether to Initiate Opioids
Non-opioid therapies are preferred for chronic pain. Opioids should be considered only when benefits for pain and function are expected to outweigh risks. Realistic treatment goals should be established before initiating therapy — complete pain elimination is not a reasonable expectation. An adequate trial of non-pharmacologic and non-opioid pharmacologic therapies should precede opioid consideration. If opioids are initiated, they should be combined with non-opioid therapies as part of multimodal treatment.
Opioid Selection, Dosage, Duration, Follow-up, and Discontinuation
Immediate-release opioids should be used when starting therapy rather than extended-release or long-acting formulations. The 2022 guideline moved away from hard dose thresholds but advises particular caution at doses of 50 morphine milligram equivalents (MME) per day or higher. Doses at or above 90 MME per day should be avoided unless carefully justified with documentation of incremental benefit. The shortest duration needed should be prescribed, with reassessment within 1-4 weeks of initiation. Importantly, the 2022 guideline explicitly cautions against abrupt tapering or discontinuation, recognizing the harms that rapid dose reduction can cause.
Assessing Risk and Addressing Harms
Risk factors for opioid-related harms should be evaluated before and during therapy. Naloxone should be prescribed for patients at increased risk of overdose. Urine drug testing (UDT) and prescription drug monitoring programs (PDMPs) should be checked before initiating and periodically during therapy. Concurrent benzodiazepine prescribing should be avoided whenever possible.
<image>Visual summary infographic of the 2022 CDC Guideline for Prescribing Opioids, organized as four quadrants representing the four recommendation areas: (1) Determining whether to initiate with a decision tree, (2) Selection and dosage with a dose-risk ladder showing escalating caution at 50 and 90 MME/day thresholds, (3) Risk assessment with icons for naloxone co-prescribing, UDT, and PDMP checks, and (4) Follow-up and discontinuation with a timeline showing recommended reassessment intervals</image>
Patient Selection
Appropriate Candidates
Appropriate candidates have well-defined pain diagnoses supported by objective findings and have had an adequate trial of non-opioid therapies (both pharmacologic and non-pharmacologic) with insufficient relief. They should have functional goals that can be measured and tracked, demonstrate understanding of risks and willingness to adhere to monitoring requirements, and not have active substance use disorder or untreated psychiatric comorbidities.
Relative Contraindications
Several factors serve as relative contraindications: active substance use disorder (opioid, alcohol, benzodiazepine, or stimulant), untreated or poorly controlled psychiatric disorders (severe depression, PTSD, personality disorders), a history of prior opioid misuse or diversion, concurrent high-dose benzodiazepine therapy, sleep-disordered breathing (obstructive sleep apnea) without CPAP therapy, and medically unexplained pain or significant psychosocial contributors without concurrent behavioral treatment.
Documentation Requirements
Thorough documentation is essential. The pain diagnosis, relevant workup, and prior treatments attempted should be recorded. Baseline pain intensity and functional status should be captured using validated measures. The risk-benefit analysis and rationale for opioid therapy should be documented along with the informed consent discussion.
Informed Consent
Informed consent for chronic opioid therapy should be as rigorous as consent for a surgical procedure. It should address the expected benefits and limitations — opioids may provide modest improvement (typically 20-30% pain reduction) but rarely eliminate chronic pain. Risks must be clearly communicated: respiratory depression, sedation, constipation, nausea, hormonal dysfunction, immunosuppression, hyperalgesia, tolerance, physical dependence, and addiction. The risk of opioid use disorder (approximately 8-12% in chronic pain patients prescribed opioids, higher with risk factors) should be stated explicitly.
Patients should be counseled about driving and occupational impairment from cognitive effects, particularly during initiation and dose changes. The monitoring plan — including urine drug tests, PDMP checks, and pill counts — should be explained along with consequences of non-adherence. Patients need to understand that opioid therapy may be tapered or discontinued if treatment goals are not met or risks outweigh benefits. Pregnancy risks, specifically neonatal opioid withdrawal syndrome (NOWS), should be discussed when relevant.
Treatment Agreements (Opioid Contracts)
Treatment agreements formalize the expectations of both provider and patient in writing. Key elements include a single prescriber and single pharmacy policy, agreement to urine drug testing at random intervals and PDMP review at each visit, a no-early-refills policy with a stated approach to lost or stolen medications, a requirement to disclose concurrent opioid prescriptions from other providers, agreement to functional goals and follow-up schedule, and clearly stated consequences of agreement violations (which should not necessarily mean immediate discontinuation).
Treatment agreements should be non-punitive and framed as mutual understanding rather than surveillance. They should be revisited and updated annually or when treatment changes occur.
<image>Sample treatment agreement template layout showing a two-column format with provider responsibilities on the left (regular follow-up, adequate pain assessment, referral to specialists, gradual tapering if needed) and patient responsibilities on the right (single pharmacy, compliance with UDT, safe storage, no sharing of medication, reporting side effects), with shared goals listed in a central banner including functional improvement targets, and a signature block at the bottom for both parties with date fields</image>
Dose Escalation Limits
The 2022 CDC guideline advises caution and careful reassessment at doses of 50 MME per day or higher. At 90 MME per day or above, the overdose risk is approximately 10-fold higher than at doses below 20 MME per day. Before escalating a dose, several questions should be addressed: Is the diagnosis correct, and has pathology been missed? Is opioid-induced hyperalgesia contributing to worsening pain? Are psychosocial or behavioral factors driving pain reports? Has tolerance developed, making rotation more appropriate than escalation?
| MME/Day Threshold | Relative Overdose Risk | Recommended Action |
|---|---|---|
| <20 MME/day | Baseline | Standard monitoring |
| 20-49 MME/day | ~2-4x baseline | Regular reassessment of risk-benefit |
| 50-89 MME/day | ~4-7x baseline | Increased caution; co-prescribe naloxone |
| ≥90 MME/day | ~10x baseline | Documented justification required; evidence of functional benefit mandatory |
Opioid rotation should be considered before dose escalation when tolerance is suspected. Naloxone should be co-prescribed for patients on 50 MME per day or higher or those with risk factors for overdose. Any dose above 90 MME per day requires documented rationale with specific evidence of functional benefit.
Evidence for Long-Term Efficacy
What the Evidence Shows
No randomized controlled trials of opioids for chronic non-cancer pain exceed 16 weeks in duration. The SPACE trial (2018) — a 12-month comparison of opioid versus non-opioid therapy for chronic back or knee osteoarthritis pain — found that opioids were not superior to non-opioid therapy for pain-related function. Opioids provided statistically greater pain intensity reduction, but the difference was clinically insignificant (0.5 points on a 0-10 scale), and the opioid group experienced more medication-related adverse effects. Observational data suggest that a subset of patients maintain stable, beneficial therapy on low-to-moderate doses, but selection bias limits interpretation.
Limitations of Current Evidence
Most chronic pain opioid trials use enriched enrollment designs that select only responders, inflating apparent efficacy. Dropout rates in long-term studies are 30-50%, primarily due to adverse effects. Functional outcomes are rarely the primary endpoint — most trials measure pain intensity alone. There is essentially no high-quality evidence that opioids improve quality of life or long-term functional status in chronic non-cancer pain.
Conditions with Better vs. Worse Evidence
Evidence is better for chronic cancer pain, sickle cell disease, and palliative care settings. Moderate evidence exists for chronic post-surgical pain and some neuropathic pain conditions. Evidence is poor for chronic low back pain, fibromyalgia, and chronic headache (where opioids may actually worsen headache via medication overuse).
| Evidence Strength | Conditions | Notes |
|---|---|---|
| Better evidence | Cancer pain, sickle cell disease, palliative care | Strongest justification for long-term use |
| Moderate evidence | Chronic post-surgical pain, neuropathic pain | Select patients may benefit |
| Poor evidence | Chronic low back pain, fibromyalgia, chronic headache | Opioids may worsen headache; SPACE trial showed no functional benefit for back/knee OA |
<image>Evidence quality pyramid for long-term opioid therapy in chronic non-cancer pain, with the broad base showing the large volume of observational and short-term trial data, narrowing upward through moderate-quality evidence (enriched enrollment RCTs up to 12-16 weeks), and an empty apex representing the absence of high-quality long-term RCTs exceeding 1 year, with the SPACE trial highlighted as a key landmark study and its primary findings summarized alongside the pyramid</image>
Practical Prescribing Framework
A systematic approach follows eight steps. First, conduct a comprehensive pain evaluation and diagnosis. Second, trial non-opioid therapies for a minimum of 4-6 weeks each. Third, perform risk assessment using tools like the ORT and SOAPP-R, check the PDMP, and obtain a baseline UDT. Fourth, conduct the informed consent discussion and establish the treatment agreement. Fifth, start a low-dose immediate-release opioid with defined functional goals. Sixth, follow up within 1-4 weeks to reassess pain, function, and adverse effects. Seventh, if beneficial, continue with scheduled monitoring (UDT, PDMP, functional assessment) every 1-3 months. Eighth, reassess the risk-benefit ratio at least annually and document ongoing justification.
Clinical Pearls
The SPACE trial is the single most important study for opioid prescribing discussions — it showed no functional advantage of opioids over non-opioid medications at 12 months. The 2022 CDC guideline deliberately moved away from rigid dose thresholds to prevent the harm of forced rapid tapers, while still recommending caution above 50 MME per day. Informed consent for chronic opioid therapy should be as rigorous as consent for a surgical procedure — the risks are comparable. Measurable functional goals (walking distance, return to work, sleep quality) should always be established rather than relying solely on pain intensity scores. Naloxone should be co-prescribed liberally — the threshold for naloxone co-prescribing should be lower than the threshold for opioid discontinuation. The absence of long-term RCT evidence does not mean opioids never work for CNCP — it means we lack high-quality evidence to guide confident long-term prescribing.
References
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
- Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872-882.
- Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448-2460.
- Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-286.
